, chronic pain affects between 8% and 30% of adults.
Apart from its effect on patients' well-being, unrelieved pain places a large economic burden on society. Back pain, for example, accounts for about one-fourth of workers' compensation claims in the United States and one-third of workers' compensation costs.
11, 12 Workdays lost due to back pain have an estimated value of $14 billion per year. 13 In addition to workers' compensation claims and lost workdays, chronic pain results in costly medical treatments, including hospitalizations, surgical procedures, and medication. 10 Pharmacologic treatment-in particular the use of long-acting opioid analgesics-is becoming an accepted part of chronic pain management. 4, 14, 15 Yet detailed information about pharmacy claims for opioids is sparse. Two studies, one in the United States 16 and one in Australia, 17 examined national trends in opioid use. However, these were population-based studies that reported aggregate data (for example, grams prescribed per 100,000 population over a period of several years), rather than prescriptionlevel data. Other studies of patients receiving opioid analgesics had very small sample sizes. Portenoy and Foley 18 , retrospectively examining 38 patients with nonmalignant pain, found that two-thirds of patients required less than 20 mg/day morphine equivalent and only four patients took more than 40 mg/day. Parrott 19 reported duration of use to be six months to 17 years for 30 nonmalignant patients in a primary care practice who received opioid analgesics. None of these studies, however, provided detailed information about pharmacy claims, such as the number of units prescribed or dispensed per day of therapy.
The aim of this study was to characterize pharmacy claims for two long-acting opioid medications used to treat pain: fentanyl transdermal system (Duragesic, Janssen Pharmaceutica Products, L.P., Titusville, New Jersey) and oxycodone HCl controlledrelease (OxyContin, Purdue Pharma L.P., Norwalk, Connecticut). We chose these two medications because they are the most commonly used medications to treat chronic nonmalignant pain. OBJECTIVE: The purpose of this study was three-fold: (1) to analyze pharmacy claims for two long-acting opioid analgesics-fentanyl transdermal system and oxycodone hydrochloride (HCl) controlled-release-using a large pharmacy and medical claims database; (2) to compare these pharmacy claims to dose administration guidelines recommended in manufacturers' prescribing information (PI); and (3) to estimate the costs (2000 $US) associated with these pharmacy claims.
DESIGN: Retrospective (1997 Retrospective ( -1999 claims of a Medicaid medical and pharmacy database were used as a data source. National Drug Codes were used to identify fentanyl transdermal system and oxycodone HCl controlled-release prescriptions. 
SETTING: California Medicaid (Medi-Cal

Cost and Utilization Patterns of Fentanyl Transdermal System and Oxycodone Hydrochloride Controlled-Release in a California Medicaid Population
According to IMS Health National Prescription Data from June 2000, fentanyl transdermal system and oxycodone HCl controlled-release capture the majority of the dollars spent on medications in the chronic pain market. The remaining medications in this group include morphine sulfate sustained-release (MS Contin, Purdue Pharma L.P., Norwalk, Connecticut), morphine sulfate, and oxycodone-acetaminophen (Percocet, Endo Pharmaceuticals Inc., Chadds Ford, Pennsylvania), with each of these medications accounting for less than 10% of the total dollars in the chronic pain market. 20 The fentanyl transdermal system provides continuous, controlled systemic delivery of fentanyl for up to 72 hours through a rectangular transparent patch. Fentanyl transdermal system is available in 25 µg/hr, 50 µg/hr, 75 µg/hr, and 100 µg/hr dosage formulations. Oxycodone HCl controlled-release is supplied in 10 mg, 20 mg, 40 mg, and 80 mg tablet strengths for oral administration.
We used pharmacy claims data to describe patterns of care among patients receiving these two medications, to estimate the costs associated with those practice patterns, and to compare pharmacy claims to dose administration guidelines recommended in manufacturers' prescribing information (PI). We used medical claims data to describe the diagnoses of patients using these two medications.
■■ Methods
We conducted a retrospective study using a 100% sample of medical and pharmacy claims data from the fee-for-service portion of California' s Medicaid (Medi-Cal) program for the period from January 1, 1997, to August 31, 1999. The present study does not use claims data from the managed care portion of Medi-Cal, which accounted for 38.7% of enrollment in 1997.
21 Each prescription record in this database lists a unique patient identification number, the date on which the drug was dispensed, the National Drug Code (NDC) for the drug dispensed, the number of units dispensed, and the number of days supply of the prescription. Because the database does not list the name or dose of the medication received, we used PriceChek PC software, produced by First DataBank Corporation, to identify the NDC codes for fentanyl transdermal system and oxycodone HCl controlledrelease and to determine the dose of each medication prescribed. The 160 mg dosage formulation of oxycodone HCl controlledrelease tablets was not made available until July 2000 and, therefore, it was not included in this study; it was later withdrawn from the market.
We divided prescriptions into two categories: those prescribed for malignant pain and those prescribed for nonmalignant pain. We defined a prescription as a malignant pain prescription if the patient receiving it had a claim with a principal or secondary diagnosis of cancer (International Classification of Diseases, Ninth Revision, Clinical Modification code [ICD-9-CM] of 140.x to 240.x) during the year prior to the prescription or on the day of the prescription. We defined a prescription as a nonmalignant pain prescription if the patient receiving it did not have a claim with a principal or secondary diagnosis of cancer during the year prior to the prescription or on the day of the prescription. The source of the ICD-9-CM codes was inpatient and outpatient claims across all settings of care (for example, hospital inpatient, hospital outpatient, emergency department, and physicians' office).
We analyzed the demographic characteristics of patients in our sample and determined the most common diagnoses of patients receiving treatment for nonmalignant pain. Because pharmacy claims do not include a diagnosis code for the condition for which the medication was prescribed, we linked medications to diagnoses temporally. Specifically, we considered only diagnoses that were received up to 30 days prior to a prescription or on the day of the prescription.
Using the prescription as the unit of analysis, we computed descriptive statistics of prescriptions used to treat malignant and nonmalignant pain, respectively. A total of 101,773 fentanyl transdermal system and oxycodone HCl controlled-release prescriptions were identified, accounting for 18,271 patients. The days supply field is not a mandatory field in the Medi-Cal database and missing values were coded as zero. We excluded 2,414 fentanyl transdermal system prescriptions (4.2% of our sample) and 1,015 oxycodone HCl controlled-release prescriptions (2.3% of our sample) where days supply was missing. After these criteria were applied, a total of 98,344 prescriptions for fentanyl transdermal system and oxycodone HCl controlled-release were included in the analysis, accounting for 17,784 patients.
We examined the dosage, number of units dispensed, and days supplied for each prescription. We then computed the mean number of units dispensed per days supplied (mean units per prescription divided by the mean days supply per prescription), and compared this to the mean number of units dispensed per day recommended in the manufacturer' s prescribing information. When performing this comparison for oxycodone HCl controlledrelease, we assumed that patients consume only one tablet at each dosing. We performed a sensitivity analysis taking into account the possibility that some patients consume more than one tablet per dosing (for example, two tablets at night and one tablet in the morning). Specifically, we calculated the mean dosings per prescription, mean dosings per day supplied, and the percentage by which actual use exceeded recommended use under alternative assumptions about the number of tablets consumed per dosing.
Next, we estimated the mean cost per day, which we calculated as the mean cost per prescription divided by the mean number of units dispensed per days supplied, and the mean cost per month, which we obtained by multiplying the mean cost per day by 30.4375 (365.25 days per year divided by 12 months). Finally, we computed the cost per year across the entire fee-forservice Medi-Cal population, which we obtained by multiplying the mean cost per prescription by the number of prescriptions per year.
Our cost estimates were based on a Medi-Cal payer perspective. We assumed that the cost of each medication was equal to
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95% of its average wholesale price (AWP), which represented the Medi-Cal drug reimbursement rate in 2000, according to information provided to the Drug Topics Red Book by the National Pharmaceutical Council in Reston, Virginia. Drug costs were based on national price lists in order to increase the generalizability of our results. Ninety-five percent of AWP was applied to pharmacy claims data from 1997 to 1999 in order to report the results using current Medi-Cal drug reimbursement rates (not including rebates). We added a dispensing fee of $4.05 per prescription minus a co-payment of $1.00 per prescription. 25 In addition, we performed a sensitivity analysis in which we considered alternative acquisition costs of each medication, ranging from 80% to 100% of AWP, as compared to 95% of AWP, which was used in the primary analysis.
In addition to raw cost data based on AWP, we felt it was important to compare the cost of oxycodone HCl controlledrelease to the recommended initial conversion doses of transdermal fentanyl. In order to accomplish this, we estimated the daily cost of oxycodone HCl controlled-release based on our findings and compared this to the cost of the recommended initial conversion dose of fentanyl transdermal system regimen, based on the manufacturer' s initial conversion dose table.
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■■ Results
Patient Characteristics
After excluding medications with invalid days supply, a total of 11,072 patients received 54,595 prescriptions for the fentanyl transdermal system between January 1, 1997, and August 31, 1999. Of these prescriptions, 24,208 (44%) were for treatment of malignant pain and 30,387 (56%) were for treatment of nonmalignant pain. A total of 7,948 patients received 43,749 prescriptions for oxycodone HCl controlled-release during the same period. Of these prescriptions, 11,492 (26%) were for treatment of malignant pain and 32,257 (74%) were for treatment of nonmalignant pain. The difference between the two groups in the mix of malignant and nonmalignant prescriptions is statistically significant ( χ 2 = 3430.70; p<0.001).
As shown in Table 1 , we divided patients into three categories: (1) 9,836 patients who received fentanyl transdermal system but did not receive oxycodone HCl controlled-release; (2) 6,712 patients who received oxycodone HCl controlled-release but did not receive fentanyl transdermal system; and (3) 1,236 patients who received both fentanyl transdermal system and oxycodone HCl controlled-release. Patients in the fentanyl transdermal system group were older (mean age of 65 years) on average than patients in the oxycodone HCl controlled-release group (mean age of 55 years) and patients who received both medications (mean age of 56 years). The race and gender mix of the three medication groups was similar. Among patients who received fentanyl transdermal system but did not receive oxycodone HCl controlled-release, 59% were white and 64% were female; among patients who received oxycodone HCl controlled-release but did not receive fentanyl transdermal system, 66% were white and 60% were female; among patients who received both medications, 64% were white and 62% were female. Reflecting the large sample size, all demographic characteristics differed significantly between the three medication groups (p<0.001 by χ 2 tests).
A total of 7.95 million individuals were eligible for Medi-Cal during the time period covered by this study. Of every 1,000 MediCal enrollees, 1.4 received fentanyl transdermal system during this period, and 1.0 received oxycodone HCl controlled-release. 
Diagnosis Characteristics
Both fentanyl transdermal system and oxycodone HCl controlledrelease were used to treat patients with a number of nonmalignant illnesses, including infection with human immunodeficiency virus (HIV), chronic airway obstruction, congestive heart failure, chronic renal failure, and lower back pain. These diagnoses were similar in both fentanyl transdermal system and oxycodone HCl controlled-release groups. A list of the top 10 diagnoses for fentanyl transdermal system and oxycodone HCl controlled-release is provided in Table 2 (listed in descending order of frequency for fentanyl transdermal system). Table 3 (see next page), Pharmacy Claims and Costs, shows after dropping prescriptions with zero days supply, 54,595 fentanyl transdermal system prescriptions and 43,749 oxycodone HCl controlled-release prescriptions remained in our sample. Taking into account prescriptions for both malignant and nonmalignant pain, the mean number of fentanyl transdermal system patches per day was 0.43, which is one patch every 2.3 days. Among oxycodone HCl controlled-release prescriptions for malignant and nonmalignant pain, the average number of tablets per day supplied was 3.4. The results were similar when the sample was limited to either prescriptions for nonmalignant pain or prescriptions for malignant pain.
Pharmacy Claims
Comparison to Manufacturers' Prescribing Information
Overall, the mean fentanyl transdermal system prescription provided 0.43 patches for each day covered by the prescription, or one patch every 2.33 days (see Table 3 ). This is 30% more patches per day than the fentanyl transdermal system prescribing information, which states that each patch may be worn continuously for 72 hours
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, implying a regimen of one patch every three days at the prescribed dosage. Manufacturers' prescribing information for transdermal fentanyl does indicate that a small number of patients may not achieve adequate analgesia using the 72 hours dosing interval and may require dosing every 48 hours.
We found that the mean prescription for oxycodone HCl controlled-release supplied 3.4 tablets per day. By comparison, the oxycodone HCl controlled-release prescribing information recommends that tablets should be taken every 12 hours. 23 For patients who take only one tablet per dosing, the average Medi-Cal prescription for oxycodone HCl controlled-release exceeds the recommended number of tablets per day by 70%. Figure 1 (see page 137) shows the discrepancy between actual and recommended number of oxycodone HCl controlled-release tablets for patients who take one tablet at each dosing.
Manufacturer' s prescribing information for oxycodone HCl controlled-release indicates that some patients may benefit from asymmetric dosing (a different dose given in the morning than in the evening), tailored to their pain pattern. The extent to which actual use exceeds recommended use is sensitive to our assumption that patients take only one tablet per dosing. However, under a broad range of plausible assumptions about the number of tablets taken at each dosing, oxycodone HCl controlled-release is taken more frequently than is recommended by the manufactur- TABLE 3 er' s prescribing information (see Table 4 ). If, for example, half of oxycodone HCl controlled-release patients average 1 tablet and half average 1.5 tablets per dosing (for example, one tablet every morning and two tablets every night), then the average number of tablets per dosing across the entire population is 1.2 and actual dosings per day exceeds recommended dosings by 41%.
Pharmacy Claims and Costs
Costs
Taking into account prescriptions for both malignant and nonmalignant pain combined, the average cost of a one-month supply of the fentanyl transdermal system was $315.08, while the average cost of a one month supply of oxycodone HCl controlled-release was $340.51 (see Table 3 ). Oxycodone HCl controlled-release patients cost $5.4 million, as compared to $5.0 million for fentanyl transdermal patients (see Table 3 ). Whether we assumed that acquisition cost was 80%, 90%, 95%, or 100% of AWP, oxycodone HCl controlled-release patients were 8% more costly than fentanyl transdermal system patients (results not shown).
Recommended Initial Conversion Dose Analysis
To compare the costs of oxycodone HCl controlled-release actual use to the recommended initial conversion dose of transdermal fentanyl, we made the following simplifying assumptions based on the mean units per day supplied reported in Table 3 and the manufacturer' s recommended initial conversion dose information for oral oxycodone presented in 
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• 80 mg oxycodone HCl controlled-release tablets: a daily supply of 5.24 tablets (419.2 mg oxycodone), can be converted to the recommended initial conversion dose of two 100 µg/hr fentanyl transdermal system patches and one 25 µg/hr fentanyl transdermal system patch every 2.0 days. Under these assumptions, which are summarized in Table 6 , the annual cost of oxycodone HCl controlled-release among all MediCal patients ($5.4 million) was 13% higher than the annual cost of the recommended initial conversion dose of fentanyl transdermal system ($4.8 million; see Figure 2 , next page).*
■■ Discussion
In this study, we used a large Medicaid claims database to describe patterns of care among patients receiving fentanyl transdermal system or oxycodone HCl controlled-release for malignant and nonmalignant conditions. We found that the number of fentanyl transdermal system patches prescribed per day exceeded the manufacturers' prescribing recommendation by 30%. If one oxycodone HCl controlled-release tablet was taken at each dosing, the number of oxycodone HCl controlled-release dosings per day exceeded the recommended amount by 70%. A limitation of this study was our inability to determine how many oxycodone HCl controlled-release tablets were taken at each dosing, since this information was not included in the claims database.
Without adjusting for the recommended initial conversion doses of transdermal fentanyl, oxycodone HCl controlled-release patients cost 8% more than fentanyl transdermal system patients. In a secondary analysis in which we compared oxycodone HCl controlledrelease to the recommended initial conversion doses of transdermal fentanyl, oxycodone HCl controlled-release patients cost 13% more than fentanyl transdermal system patients. This percentage increase represents a potential annual cost savings of $0.6 million among Medi-Cal patients. Although this cost difference is based on the manufacturer' s recommended initial conversion doses, it is important to realize that the dosing convention used in this analysis is based on the fentanyl transdermal system prescribing information (see Table 5 ); these results may vary depending upon which recommended initial conversion dose is used.
Based on our review of 10 abstracts obtained from the MED-LINE database (January 1994-November 2001) using the search terms "claims analysis" or "insurance claims" coupled with "Duragesic," "transdermal fentanyl," "OxyContin," "oxycodone," "analgesia," "analgesic," or "opioid," this is the first study to use a large pharmacy claims database to analyze pharmacy claims for opioid analgesics. Through other searches, we identified four studies that examined the use of opioids using methods other than analysis of pharmacy claims, but these studies provided little or no information comparing these pharmacy claims to the manufacturers' recommended prescribing information.
This study was designed to describe-not explain-pharmacy claims. We speculate that the recommended dosing schedules for both products provide inadequate pain control for many patients. Future research evaluating the reasons for the discrepancy between the manufacturers' prescribing information and pharmacy claims is warranted.
The Medi-Cal database, like all claims databases, was not created for research purposes. Because the Medi-Cal database includes only one secondary diagnosis code on each claim, incomplete capture of diagnosis is a limitation of this study, as well as other studies that use administrative data. Nevertheless, previous studies have reported a high degree of reliability and validity of Medicaid prescription drug data. 24, 25 Additionally, pharmacy claims databases provide information about medication dispensing dates, as opposed to the actual daily intake of the medications. We cannot rule out the possibility, therefore, that a patient receiving three tablets per day is being dosed q12 hours (for example, one tablet in the morning and two tablets at night).
This analysis was based on a Medicaid population, which consists of a disproportionate number of female and low-income indi- To some extent, the differences in cost and utilization patterns may reflect differences in the demographic characteristics in the two groups of patients. Patients in the fentanyl transdermal system group were less costly than oxycodone HCl controlled-release patients, but they also were older and a larger percentage of prescriptions were for treatment of malignant pain. In the present study, roughly 70% of fentanyl transdermal system patients and 47% of oxycodone HCl controlled-release patients were age 55 or over. In addition, 44% of fentanyl transdermal system prescriptions and 26% of oxycodone HCl controlled-release prescriptions were for treatment of malignant pain. The manufacturer' s prescribing information for fentanyl transdermal system suggests a reduced initial dose for the elderly because these patients may have altered pharmacokinetics. Similarly, the manufacturer' s prescribing information for oxycodone HCl controlled-release suggests a starting dose of one-third to one-half of the usual dosage for geriatric, debilitated, non-tolerant patients. Also, a recent clinical review suggests a reduced starting dose in opioid-naïve elderly patients. 26 The clinical review 26 also indicates that opioid doses needed to relieve malignant pain are often higher than those needed for treatment of nonmalignant pain. After considering the older population and larger percentage of malignant pain in the fentanyl transdermal system group (the former, which may result in a lower starting dose, and the latter, which may result in a higher dose for adequate pain relief), it is unlikely that these imbalances would fully account for the difference in the amounts by which the drugs exceeded the recommended manufacturers' prescribing information (by 30% for the fentanyl transdermal system group versus 70% for the oxycodone HCl controlled-release group, assuming that patients took one oxycodone HCl controlled-release tablet per dosing).
If older patients require less pain medication than younger patients or if patients being treated for malignant pain require more pain medication than those being treated for nonmalignant pain, then age and pain category (malignant versus nonmalignant) could confound the relationship between the drug group and utilization. Additional research is recommended to better understand the impact of patient age and pain category on the pharmacy claims of these long-acting opioids.
Our cost estimates were developed using 95% of the AWP plus a dispensing fee minus a co-payment. We recognize that the true cost to Medi-Cal is less than 95% of AWP once rebates are taken into account. 27 When we conducted a sensitivity analysis in which we considered alternative acquisition costs of each medication ranging from 80% to 100% of AWP, our findings and inferences regarding the cost differential between fentanyl transdermal system and oxycodone HCl controlled-release did not change.
■■ Conclusion
The manner in which fentanyl transdermal system and oxycodone HCl controlled-release are used appears to often be inconsistent Cost and Utilization Patterns of Fentanyl Transdermal System and Oxycodone Hydrochloride Controlled-Release in a California Medicaid Population with manufacturers' prescribing information. When actual pharmacy claims were accounted for, oxycodone HCl controlledrelease contributed an annual cost of $0.6 million above the recommended initial conversion dose of fentanyl transdermal system. Our findings underscore the need for additional studies to better understand the pharmacy claims in large patient populations, such as managed care and pharmacy benefit management organizations. 
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